The Active Pharmaceutical Ingredients (API) Innovation Center aims to “address health security and foster job growth.” It will seek to advance that mission by having businesses, researchers, academics, and experts work together to find new ways in which the U.S. can boost production of pharmaceutical ingredients.
“The API Innovation Center at Cortex is dedicated to addressing the fragility in the U.S. API supply chain and the risks to health security,” said Tony Sardella, chair of the API Innovation Center. “Missouri, as the number-one-ranked state in the country for production of pharmaceutical APIs, is uniquely positioned to help secure the domestic supply chain. Promising advancements, such as continuous flow manufacturing technologies, offer the opportunity for the U.S. to address our health security risks. The center will steward the necessary collaborations for these innovative technologies to realize their full potential.”
Organizations currently involved in the API Innovation Center include Cortex, BioSTL, Mallinckrodt Specialty Generics, Continuity Pharma, AMIC and Apertus Pharmaceuticals.
Missouri is a leader in the health innovation industry. Missouri’s bioscience industry employs approximately 56,000 highly skilled individuals within more than 4,900 companies. Additionally, Missouri is home to some of the most prestigious hospitals, medical schools, and health companies in the world and was a key location in the development of the Pfizer COVID-19 vaccine.